✉ Email this page to a colleague
« Back to Dashboard
Morphabond Er is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-three patent family members in ten countries.
The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
A generic version of MORPHABOND ER was approved as morphine sulfate by HOSPIRA on May 11th, 1988.
Summary for MORPHABOND ER
|Raw Ingredient (Bulk) Api Vendors:||25|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for MORPHABOND ER|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for MORPHABOND ER|
|DailyMed Link:||MORPHABOND ER at DailyMed|
MORPHABOND ER is protected by two US patents.
Patents protecting MORPHABOND ER
See the table below for patents covering MORPHABOND ER around the world.
|Country||Patent Number||Title||Estimated Expiration|
|Mexico||336789||FARMACOS RESISTENTES AL ABUSO, METODO DE USO Y METODO DE FABRICACION. (ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING.)||See Plans and Pricing|
|Japan||5965583||See Plans and Pricing|
|Australia||2009282376||Pharmaceutical compositions configured to deter dosage form splitting||See Plans and Pricing|
|Canada||2923102||MEDICAMENTS RESISTANT AUX ABUS, PROCEDES D'UTILISATION ET DE FABRICATION (ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING)||See Plans and Pricing|
|Australia||2008286914||Abuse resistant drugs, method of use and method of making||See Plans and Pricing|
|Australia||2015200009||Abuse resistant drugs, method of use and method of making||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|